Sentences with phrase «sofosbuvir combination»

The ledipasvir / sofosbuvir combination, Harvoni ®, is now FDA - approved for numerous types of HCV infection, including the most common form in the US and Europe.

301 chronically infected adults were treated with the ravidasvir / sofosbuvir combination for 12 weeks for patients without cirrhosis of the liver, and for 24 weeks for those with compensated cirrhosis.

Not exact matches

It has confirmed that 24 weeks is the optimal duration for a sofosbuvir and ribavirin combination in GT - 3 patients, whilst also finding that sofosbuvir and ribavirin with peginterferon for 12 weeks resulted in the highest SVR12 rates observed to date in a Phase 3 study,» said Professor Tom Hemming Karlsen, Scientific Committee Member, European Association for the Study of the Liver (EASL).

Results presented today at The International Liver Congress ™ 2015 demonstrate that hepatitis C (HCV)- infected genotype - 3 (GT - 3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date.

«The results of the ION studies demonstrated highly satisfactory cure rates with a fixed dose combination of sofosbuvir / ledipasvir among patients with genotype 1 HCV infection without the use of either injectable interferon, which causes miserable flu - like symptoms, or ribavirin, an antiviral pill associated with a variety of troublesome side effects, including anemia and rash,» Professor Peck - Radosavljevic continued.

Results from three Phase III clinical trials (ION - 1, ION - 2 and ION - 3) evaluating the investigational once - daily fixed - dose combination of the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400 mg and the NS5A inhibitor ledipasvir (LDV) 90 mg, with and without ribavirin (RBV), for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection have been presented at the International Liver CongressTM 2014.

Results presented today at The International Liver Congress ™ 2015 show that the sofosbuvir (SOF) / daclatasvir (DCV) treatment combination is effective amongst hepatitis C virus (HCV) genotype - 1 mono - infected patients.

«The cohort study has found that the sofosbuvir / daclatasvir combination is associated with a high rate of SVR4 in difficult - to - treat patients infected by genotype - 1 hepatitis C.

This is one of the first real - life studies looking into sofosbuvir / daclatasvir combinations and has demonstrated that this is a good therapeutic option for these patients.

«Sofosbuvir / daclatasvir combination effective treatment for difficult - to - treat hep C patients.»

The higher cure rate and lessened side - effects of treating patients with an all - oral combination of ledipasvir and sofosbuvir (LDV / SOF) results in greatly reduced absenteeism and improved workplace productivity that can translate into enormous benefit, according to the new economic model used by researchers at Inova Fairfax Medical Campus, VA..

Today, with just 12 weeks of treatment with drug combinations that use Sofia's drug, sofosbuvir (Sovaldi ®) as the backbone of Harvoni ®, almost all those treated are cured.

Examples of DAAs, which come in pill form, are Olysio (simeprevir); Sovaldi (sofosbuvir), which is used in combination with Olysio; Daklinza (daclatasvir); and Harvoni (a combination of ledipasvir and sofosbuvir).